0.00Open0.07Pre Close0 Volume143 Open Interest11.50Strike Price0.00Turnover8882.88%IV53.25%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-3DDays to Expiry0.07Extrinsic Value100Contract SizeAmericanOptions Type0.0884Delta0.0854Gamma107.86Leverage Ratio-60.7664Theta0.0000Rho9.53Eff Leverage0.0000Vega
Altimmune Stock Discussion
$Altimmune (ALT.US)$
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®.
The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascul...
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
Will a partner be announced or are the rumours true a buy out is eminent..!
No comment yet